Fusion genes in solid tumors: An emerging target for cancer diagnosis and treatment

Chinese Journal of Cancer

Volumn 32, Issue 11, 2013, Pages 594-603

  Parker, Brittany C ^a,b   Zhang, Wei ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer genomics; Chromosomal instability; Fusion genes; Therapy; Tumorigenesis

Indexed keywords

CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; TRANSFORMING ACIDIC COILED COIL CONTAINING PROTEIN 3; UNCLASSIFIED DRUG;

ABL1 PROTO ONCOGENE; ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ALK PROTO ONCOGENE; ATF 2 PROTO ONCOGENE; BAG4 PROTO ONCOGENE; BAIAP2L1 PROTO ONCOGENE; BCOR PROTO ONCOGENE; BCR PROTO ONCOGENE; BLADDER CANCER; BRAF PROTO ONCOGENE; BREAST METASTASIS; C11ORF20 PROTO ONCOGENE; CANCER DIAGNOSIS; CANCER THERAPY; CARCINOGENICITY; CCNB3 PROTO ONCOGENE; CHROMOSOMAL INSTABILITY; CHRONIC MYELOID LEUKEMIA; CLEAR CELL SARCOMA; COLORECTAL CANCER; DDIT3 PROTO ONCOGENE; DNA SEQUENCE; E26 PROTO ONCOGENE; EIF3E PROTO ONCOGENE; EML4 PROTO ONCOGENE; ESRRA PROTO ONCOGENE; ETS PROTO ONCOGENE; ETV6 PROTO ONCOGENE; EWING SARCOMA; EWSR1 PROTO ONCOGENE; FGFR1 PROTO ONCOGENE; FGFR2 PROTO ONCOGENE; FGFR3 PROTO ONCOGENE; FUS PROTO ONCOGENE; FUSION GENE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE REARRANGEMENT; GENE TARGETING; GENE TRANSLOCATION; GENOMIC INSTABILITY; GLIOBLASTOMA; GPR128 PROTO ONCOGENE; HUMAN; IGF1R PROTO ONCOGENE; IGFBP 3 PROTO ONCOGENE; IMMUNOGLOBULIN GENE; KIAA1549 PROTO ONCOGENE; KIAA1967 PROTO ONCOGENE; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAML2 PROTO ONCOGENE; MECT1 PROTO ONCOGENE; NFIB PROTO ONCOGENE; NTRK3 PROTO ONCOGENE; ONCOGENE MYB; ONCOGENE MYC; PAX8 PROTO ONCOGENE; PHILADELPHIA 1 CHROMOSOME; PHOTOAGING; PILOCYTIC ASTROCYTOMA; POLYMERASE CHAIN REACTION; PPARG PROTO ONCOGENE; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; PROTO ONCOGENE; PTPRK PROTO ONCOGENE; REVIEW; RSPO3 PROTO ONCOGENE; SECRETORY BREAST CARCINOMA; SEROUS OVARIAN CANCER; SET PROTO ONCOGENE; SFPQ PROTO ONCOGENE; SLC45A3 PROTO ONCOGENE; SMALL ROUND CELL TUMORS OF THE BONE; SOLID TUMOR; SS18 PROTO ONCOGENE; SSX PROTO ONCOGENE; SYNOVIAL SARCOMA; TACC1 PROTO ONCOGENE; TACC3 PROTO ONCOGENE; TFE3 PROTO ONCOGENE; TFG PROTO ONCOGENE; THYROID FOLLICULAR CARCINOMA; TMPRSS2 PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

CHROMOSOMAL INSTABILITY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; NEOPLASMS; ONCOGENE PROTEINS, FUSION; ONCOGENES; RECOMBINATION, GENETIC; TRANSLOCATION, GENETIC;

EID: 84887375179     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.013.10178     Document Type: Review

References (102)

1. Gilbert W, Maxam A. The nucleotide sequence of the lac operator. Proc Natl Acad Sci U S A, 1973,70:3581-3584.
2. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chainterminating inhibitors. Proc Natl Acad Sci U S A, 1977,74:5463-5467.
3. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science, 1985,230:1350-1354.
4. Schuster SC. Next-generation sequencing transforms today's biology. Nat Methods, 2008,5:16-18.
5. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 1973,243:290-293.
6. Lifshitz B, Fainstein E, Marcelle C, et al. Bcr genes and transcripts. Oncogene, 1988,2:113-117.
7. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science, 1960,132:1497.
8. Dreazen O, Klisak I, Jones G, et al. Multiple molecular abnormalities in Ph1 chromosome positive acute lymphoblastic-leukemia. Brit J Haematol, 1987,67:319-374.
9. Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature, 1985,315:550-554.
10. Manolov G, Manolova Y. Marker band in one chromosome-14 from Burkitt lymphomas. Nature, 1972,237:33-34.
11. Zech L, Haglund U, Nilsson K, et al. Characteristic chromosomalabnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer, 1976,17:47-56.
12. Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A, 1982,79:7824-7827.
13. Park MDLaA. New hope for cancer. Time Magazine. San Francisco: Time Inc., May 28, 2001.
14. Larson RA, Kondo K, Vardiman JW, et al. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med, 1984,76:827-841.
15. Borrow J, Goddard AD, Sheer D, et al. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science, 1990,249:1577-1580.
16. Stefanaki C, Stratigos A, Katsambas A. Topical retinoids in the treatment of photoaging. J Cosmet Dermatol, 2005,4:130-134.
17. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 1988,72:567-572.
18. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood, 1990,76:1704-1709.
19. Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med, 1991,324:1385-1393.
20. Parker BC, Annala MJ, Cogdell DE, et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest, 2013,123:855-865.
21. Singh D, Chan JM, Zoppoli P, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science, 2012,337:1231-1235.
22. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet, 2013,22:795-803.
23. Wu YM, Su FY, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov, 2013,3:636-647.
24. Borden EC, Baker LH, Bell RS, et al. Soft tissue sarcomas of adults: State of the translational science. Clin Cancer Res, 2003,9:1941-1956.
25. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol, 2010,11:184-192.
26. Aurias A, Rimbaut C, Buffe D, et al. Chromosomal translocations in Ewing's sarcoma. New Engl J Med, 1983,309:496-497.
27. Turc-Carel C, Philip I, Berger MP, et al. Chromosomal translocation (11; 22) in cell lines of Ewing's sarcoma. C R Seances Acad Sci III, 1983,296:1101-1103. [in French]
28. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome-translocation in human tumors. Nature, 1992,359:162-165.
29. Scotlandi K, Benini S, Sarti M, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res, 1996,56:4570-4574.
30. Prieur A, Tirode F, Cohen P, et al. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol, 2004,24:7275-7283.
31. Hancock JD, Lessnick SL. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle, 2008,7:250-256.
32. Shelton JG, Steelman LS, White ER, et al. Synergy between PI3K/ AKT and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle, 2004,3:372-379.
33. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett, 2003,195:127-137.
34. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol, 2002,3:298-302.
35. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 2000,92:1472-1489.
36. Iwasa T, Okamoto I, Suzuki M, et al. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells. Clin Cancer Res, 2009,15:5117-5125.
37. Olmos D, Martins AS, Jones RL, et al. Targeting the insulinlike growth factor 1 receptor in Ewing's sarcoma: reality and expectations. Sarcoma, 2011,2011:402508.
38. Szuhai K, Ijszenga M, de Jong D, et al. The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology. Clin Cancer Res, 2009,15:2259-2268.
39. Haldar M, Randall RL, Capecchi MR. Synovial sarcoma: from genetics to genetic-based animal modeling. Clin Orthop Relat Res, 2008,466:2156-2167.
40. Turc-Carel C, Dal Cin P, Limon J, et al. Involvement of chromosome X in primary cytogenetic change in human neoplasia: nonrandom translocation in synovial sarcoma. Proc Natl Acad Sci U S A, 1987,84:1981-1985.
41. Clark J, Rocques PJ, Crew AJ, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet, 1994,7:502-508.
42. Crew AJ, Clark J, Fisher C, et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J, 1995,14:2333-2340.
43. Skytting B, Nilsson G, Brodin B, et al. A novel fusion gene, SYTSSX4, in synovial sarcoma. J Natl Cancer Inst, 1999,91:974-975.
44. Nagai M, Tanaka S, Tsuda M, et al. Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha. Proc Natl Acad Sci U S A, 2001,98:3843-3848.
45. Lim FL, Soulez M, Koczan D, et al. A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomas. Oncogene, 1998,17:2013-2018.
46. Su L, Sampaio AV, Jones KB, et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. Cancer Cell, 2012,21:333-347.
47. Ito T, Ouchida M, Morimoto Y, et al. Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett, 2005,224:311-319.
48. Liu S, Cheng H, Kwan W, et al. Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models. Mol Cancer Ther, 2008,7:1751-1761.
49. Meis-Kindblom JM. Clear cell sarcoma of tendons and aponeuroses: a historical perspective and tribute to the man behind the entity. Adv Anat Pathol, 2006,13:286-292.
50. Bridge JA, Borek DA, Neff JR, et al. Chromosomal-abnormalities in clear cell-sarcoma. Implications for histogenesis. Am J Clin Pathol, 1990,93:26-31.
51. Zucman J, Delattre O, Desmaze C, et al. EWS and ATF-1 gene fusion induced by t(12-22) translocation in malignant-melanoma of soft parts. Nat Genet, 1993,4:341-345.
52. Goransson M, Andersson MK, Forni C, et al. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ. Oncogene, 2009,28:270-278.
53. Berman JJ. Tumor taxonomy for the developmental lineage classification of neoplasms. BMC cancer, 2004,4:88.
54. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res, 2009,53:171-184.
55. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 2005,310:644-648.
56. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res, 2006,66:3396-3400.
57. Yu JD, Yu JJ, Mani RS, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell, 2010,17:443-454.
58. Esgueva R, Perner S, LaFargue CJ, et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Modern Pathol, 2010,23:539-546.
59. Katoh M. Cancer genomics and genetics of FGFR2 (Review). Int J Oncol, 2008,33:233-237.
60. Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell, 2002,2:367-376.
61. Knezevich SR, McFadden DE, Tao W, et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet, 1998,18:184-187.
62. Wai DH, Knezevich SR, Lucas T, et al. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells. Oncogene, 2000,19:906-915.
63. Tognon C, Garnett M, Kenward E, et al. The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation. Cancer Res, 2001,61:8909-8916.
64. Zeegers MPA, Tan FES, Dorant E, et al. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer, 2000,89:630-639.
65. Chen G, Li T, Zhang L, et al. Src-stimulated IRTKS phosphorylation enhances cell migration. FEBS lett, 2011,585:2972-2978.
66. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 2011,61:212-236.
67. Watson AJ, Collins PD. Colon cancer: a civilization disorder. Dig Dis, 2011,29:222-228.
68. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet, 2010,375:1030-1047.
69. Seshagiri S, Stawiski EW, Durinck S, et al. Recurrent R-spondin fusions in colon cancer. Nature, 2012,488:660-664.
70. Kazanskaya O, Glinka A, Barrantes ID, et al. R-Spondin2 is a secreted activator of Wnt/beta-catenin signaling and is required for Xenopus myogenesis. Dev Cell, 2004,7:525-534.
71. McArdle L, Rafferty M, Maelandsmo GM, et al. Protein tyrosine phosphatase genes downregulated in melanoma. J Invest Dermatol, 2001,117:1255-1260.
72. Nakamura M, Kishi M, Sakaki T, et al. Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res, 2003,63:737-741.
73. Scrima M, De Marco C, De Vita F, et al. The nonreceptor-type tyrosine phosphatase PTPN13 is a tumor suppressor gene in nonsmall cell lung cancer. Am J Pathol, 2012,180:1202-1214.
74. Mo W, Zhang J, Li X, et al. Identification of novel AR-targeted microRNAs mediating androgen signalling through critical pathways to regulate cell viability in prostate cancer. PloS one, 2013,8:e56592.
75. Browning KS, Gallie DR, Hershey JWB, et al. Unified nomenclature for the subunits of eukaryotic initiation factor 3. Trends Biochem Sci, 2001,26:284-284.
76. Salzman J, Marinelli RJ, Wang PL, et al. ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma. PLoS Biol, 2011,9:e1001156.
77. Ariazi EA, Clark GM, Mertz JE. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res, 2002,62:6510-6518.
78. Sun PM, Sehouli J, Denkert C, et al. Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells. J Mol Med-(Berl), 2005,83:457-467.
79. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002,346:92-98.
80. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007,448:561-566.
81. Takezawa K, Okamoto I, Nishio K, et al. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Clin Cancer Res, 2011,17:2140-2148.
82. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 2010,363:1693-1703.
83. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med, 2012,18:375-377.
84. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med, 2012,18:378-381.
85. Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome research, 2012,22:2109-2119.
86. Fordice J, Kershaw C, El-Naggar A, et al. Adenoid cystic carcinoma of the head and neck-predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg, 1999,125:149-152.
87. Qian F, Kruse U, Lichter P, et al. Chromosomal localization of the 4 genes (NFIA, B, C, and X) for the human transcription factor nuclear factor-I by FISH. Genomics, 1995,28:66-73.
88. Geurts JMW, Schoenmakers EFPM, Roijer E, et al. Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas. Oncogene, 1998,16:865-872.
89. Persson M, Andren Y, Mark J, et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A, 2009,106:18740-18744.
90. Tonon G, Modi S, Wu LZ, et al. t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet, 2003,33:208-213.
91. Artavanis-Tsakonas S, Matsuno K, Fortini ME. Notch signaling. Science, 1995,268:225-232.
92. Garcia JJ, Hunt JL, Weinreb I, et al. Fluorescence in situ hybridization for detection of MAML2 rearrangements in oncocytic mucoepidermoid carcinomas: Utility as a diagnostic test. Hum Pathol, 2011,42:2001-2009.
93. Mitchell RS, Kumar V, Abbas AK et al. Robbins basic pathology. 8th edition. Philadelphia: W B Saunders Co, 2007.
94. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science, 2000,289:1357-1360.
95. Jones JR, Barrick C, Kim KA, et al. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci U S A, 2005, 102:6207-6212.
96. Powell JG, Wang XY, Allard BL, et al. The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. Oncogene, 2004,23:3634-3641.
97. Mulders PF, Brouwers AH, Hulsbergen-van der Kaa CA, et al. Guideline 'Renal cell carcinoma'. Ned Tijdschr Geneeskund, 2008,152:376-380. [in Dutch]
98. Clark J, Lu YJ, Sidhar SK, et al. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene, 1997,15:2233-2239.
99. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature, 2013,499:43-49.
100. Park BJ, Kim HK, Sade B, et al. Epidemiology. Lee JH (ed). Meningiomas: diagnosis, treatment, and outcome. London: Springer, 2008.
101. Jones DT, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res, 2008,68:8673-8677.
102. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature, 2002,417:949-954.